Comparative Pharmacology
Head-to-head clinical analysis: DERMACORT versus ELOCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMACORT versus ELOCON.
DERMACORT vs ELOCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response.
Elocon (mometasone furoate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to increased synthesis of lipocortins that inhibit phospholipase A2, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene formation. It also suppresses cytokine production and inflammatory cell migration.
Apply a thin film to affected area twice daily (every 12 hours) for up to 2 weeks.
Apply a thin film to affected skin area once daily. Use no more than 45 g per week.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for hydrocortisone, the active component. Due to its short half-life, it requires multiple daily doses for sustained effect.
Terminal elimination half-life approximately 5-7 hours after topical application. Systemic half-life is short, limiting systemic accumulation with topical use.
Primarily hepatic metabolism; metabolites are excreted renally (~75% as glucuronide and sulfate conjugates) and fecally (~25%). Less than 5% of the dose is excreted unchanged in urine.
Primarily hepatic metabolism; metabolites excreted renally and in feces. Approximately 60% of a topical dose is excreted in urine as metabolites, 30% in feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid